Skip to main content
. 2019 Jul 29;9:10930. doi: 10.1038/s41598-019-47248-8

Figure 1.

Figure 1

Effect of imatinib on BCR-ABL, HA and CD44 levels. (A) K562 and Kv562 cells were treated either with imatinib, HA (high molecular weight) or a combination of both for 24 h. Expression levels of BCR-ABL were evaluated by WB. Results are expressed as: BCR-ABL index = (BCR-ABL/β-actin)treated/(BCR-ABL /β-actin)untreated. Data are expressed as the mean ± SEM of at least three independent experiments ##p < 0.01 treated vs. untreated cells, ns = non-significant difference (p > 0.05) between the treatments indicated. (B) Levels of HA in culture supernatant were evaluated by ELISA after the treatment with either imatinib or 4MU for 72 h. Values are expressed as the mean ± SEM (ng HA/106cells/72 h) of at least three independent experiments. ###p < 0.001 and ##p < 0.01, treated vs. untreated cells and **p < 0.01 between the treatments indicated. (C) Both cell lines were treated with imatinib for 24 h and the CD44 expression (with or without permeabilization) was then evaluated by FC. U937 cells were used as BCR-ABL negative control. Results are expressed as mean ± SEM of CD44 positive cells (%) of at least three independent experiments. ##p < 0.01, #p < 0.01, treated vs. untreated cells and ***p < 0.001, **p < 0.01 between the treatments indicated.